Featured Publications
Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction
Back J, Nguyen MN, Li L, Lee S, Lee I, Chen F, Gillinov L, Chung YH, Alder KD, Kwon HK, Yu KE, Dussik CM, Hao Z, Flores MJ, Kim Y, Ibe IK, Munger AM, Seo SW, Lee FY. Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction. Bone Research 2021, 9: 43. PMID: 34588427, PMCID: PMC8481290, DOI: 10.1038/s41413-021-00158-w.Peer-Reviewed Original ResearchCancer-induced bone destructionBreast cancer cellsOsteolytic breast cancerBone homeostasisCancer growthCancer cellsBone destructionInflammatory osteolysisBreast cancerBreast cancer-induced bone destructionOsteolytic breast cancer metastasesPromising adjuvant therapyERK1/2 activationMEK1 expressionBreast cancer metastasisMetastatic breast cancer cellsActivation of pERK1/2Inflammatory conversionAdjuvant therapyPathological fracturesHuman pathological specimensBone microenvironmentPathological specimensSkeletal diseasePathway inhibitor
2019
Metastatic Cancers to Bone: An Overview and Cancer-Induced Bone Loss.
Ibe IK, Sahlstrom A, White A, Henderson SE, Lee FY. Metastatic Cancers to Bone: An Overview and Cancer-Induced Bone Loss. Instructional Course Lectures 2019, 68: 547-556. PMID: 32032068.Peer-Reviewed Original ResearchConceptsCancer-induced bone lossBone lossBone metastasesMetastatic bone diseaseCancer cellsDegree of osteolysisNormal bone homeostasisBenefit of patientsOsteolytic metastasesSkeletal metastasesPatient functionSurgical stabilizationWorse prognosisLocal bone massBone massMetastatic cancerBone diseaseRadiation therapyTherapeutic modalitiesBone homeostasisImmune systemOverall outcomeMetastasisBone remodelingPatients
2018
Immuno-oncologic Approach to Musculoskeletal Tumors
Ibe I, Sahlstrom A, Nguyen M, Lindskog D, Friedlaender G, Lee F. Immuno-oncologic Approach to Musculoskeletal Tumors. Techniques In Orthopaedics 2018, 33: 140-147. DOI: 10.1097/bto.0000000000000305.Peer-Reviewed Original ResearchImmune systemImmuno-oncologic therapiesSoft tissue sarcomasHost immune surveillanceActive immune responseTreatment of boneImmune therapyTumor burdenTissue sarcomasTreatment of cancerTreatment optionsMusculoskeletal tumorsComprehensive careImproved outcomesImmune surveillanceImmune responseOrthopedic oncologyMalignant cellsImmunotherapyCancer cellsPrecision medicineDistant sitesPatientsUnderlying mechanismTherapyMolecular Targeted Therapy Approach to Musculoskeletal Tumors
Ibe I, Haynes M, Koo A, Lindskog D, Friedlaender GE, Lee FY. Molecular Targeted Therapy Approach to Musculoskeletal Tumors. Techniques In Orthopaedics 2018, 33: 135-139. PMID: 36186916, PMCID: PMC9524233, DOI: 10.1097/bto.0000000000000298.Peer-Reviewed Original Research